 |
31 Diseases |  |
42 Trials |
|
42 Trials |  |
576 News |  |
| «12345678 |
- Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Trial initiation date: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) - Nov 19, 2012
P3, N=24, Terminated, Sponsor: Eisai Inc.
Initiation date: Dec 2011 --> Apr 2012
- | Doptelet (avatrombopag) / SOBI
Trial completion: A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 (clinicaltrials.gov) - Aug 12, 2012
P1, N=28, Completed, Sponsor: Eisai Inc.
Initiation date: Dec 2011 --> Apr 2012 Recruiting --> Completed
- | Doptelet (avatrombopag) / SOBI
Trial completion: Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. (clinicaltrials.gov) - May 17, 2012
P1, N=36, Completed, Sponsor: Eisai Inc.
Recruiting --> Completed Recruiting --> Completed
- | Doptelet (avatrombopag) / SOBI
Trial completion: Single and Multiple Dose Asian Bridging Study (clinicaltrials.gov) - Apr 3, 2012
P1, N=36, Completed, Sponsor: Eisai Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Doptelet (avatrombopag) / SOBI
Trial completion: Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects (clinicaltrials.gov) - Mar 7, 2012
P1, N=84, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- | Doptelet (avatrombopag) / SOBI
New P1 trial: A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 (clinicaltrials.gov) - Mar 6, 2012
P1, N=28, Completed, Sponsor: Eisai Inc.
- |||| Doptelet (avatrombopag) / SOBI
Trial completion: Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures (clinicaltrials.gov) - Jan 30, 2012
P2, N=136, Completed, Sponsor: Eisai Inc.
Recruiting --> Completed Recruiting --> Completed
- |||| Doptelet (avatrombopag) / SOBI
Trial completion: Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 13, 2011
P2, N=64, Completed, Sponsor: Eisai Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Doptelet (avatrombopag) / SOBI
New P3 trial: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) - Sep 20, 2011
P3, N=49, Completed, Sponsor: Eisai Inc.
- | Doptelet (avatrombopag) / SOBI
New P1 trial: Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. (clinicaltrials.gov) - Sep 18, 2011
P1, N=36, Completed, Sponsor: Eisai Inc.
- Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
New P3 trial: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) - Sep 12, 2011
P3, N=24, Terminated, Sponsor: Eisai Inc.